Evidence map›Paper›PMID 24877075›Full record

Trial reportBioMed research international2014

A founder large deletion mutation in Xeroderma pigmentosum-Variant form in Tunisia: implication for molecular diagnosis and therapy.

Mariem Ben Rekaya, Nadia Laroussi, Olfa Messaoud, Mariem Jones, Manel Jerbi, Chokri Naouali, Yosra Bouyacoub, Mariem Chargui, Rym Kefi, Becima Fazaa and 7 more

Abstract readClinical Trial
In one paragraph

Trial report in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Genetics and genomic medicine in Tunisia.Molecular genetics & genomic medicine · 2018
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mariem Ben RekayaLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia.
Nadia LaroussiLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia.
Olfa MessaoudLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia.
Mariem JonesLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia ; Département de Dermatologie, Hôpital Charles Nicolle de Tunis, 1006 Tunis, Tunisia.
Manel JerbiLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia.
Chokri NaoualiLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia.ORCID 0000-0002-5237-2573
Yosra BouyacoubLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia.
Mariem CharguiLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia.
Rym KefiLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia.
Becima FazaaLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia ; Département de Dermatologie, Hôpital Charles Nicolle de Tunis, 1006 Tunis, Tunisia.
Mohamed Samir BoubakerLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia ; Département d'Anatomie-Pathologique Humaine et Expérimentale, Institut Pasteur de Tunis, 1002 Tunis, Tunisia.
Hamouda BoussenDépartement d'Oncologie Médicale, Hôpital Abderrahman Mami, 2080 Ariana, Tunisia.
Mourad MokniDépartement d'Oncologie Médicale, Hôpital La Rabta de Tunis, 1007 Tunis, Tunisia.
Sonia AbdelhakLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia.
Mohamed ZghalDépartement de Dermatologie, Hôpital Charles Nicolle de Tunis, 1006 Tunis, Tunisia.
Aida KhaledLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia ; Département de Dermatologie, Hôpital Charles Nicolle de Tunis, 1006 Tunis, Tunisia.
Houda Yacoub-YoussefLaboratoire de Génomique Biomédicale et Oncogénétique (LR 11 IPT 05), Institut Pasteur de Tunis, Université de Tunis El Manar, El Manar I, BP 74, 13 Place Pasteur 1002 Tunis Belvédère, 2092 Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xeroderma pigmentosum Variant (XP-V) form is characterized by a late onset of skin symptoms. Our aim is the clinical and genetic investigations of XP-V Tunisian patients in order to develop a simple tool for early diagnosis. We investigated 16 suspected XP patients belonging to ten consanguineous families. Analysis of the POLH gene was performed by linkage analysis, long range PCR, and sequencing. Genetic analysis showed linkage to the POLH gene with a founder haplotype in all affected patients. Long range PCR of exon 9 to exon 11 showed a 3926 bp deletion compared to control individuals. Sequence analysis demonstrates that this deletion has occurred between two Alu-Sq2 repetitive sequences in the same orientation, respectively, in introns 9 and 10. We suggest that this mutation POLH NG_009252.1: g.36847_40771del3925 is caused by an equal crossover event that occurred between two homologous chromosomes at meiosis. These results allowed us to develop a simple test based on a simple PCR in order to screen suspected XP-V patients. In Tunisia, the prevalence of XP-V group seems to be underestimated and clinical diagnosis is usually later. Cascade screening of this founder mutation by PCR in regions with high frequency of XP provides a rapid and cost-effective tool for early diagnosis of XP-V in Tunisia and North Africa.

Indexed as

Base SequenceFounder EffectHaplotypesSequence DeletionAdolescentAdultChildChild, PreschoolDNA-Directed DNA PolymeraseExonsFemaleHumansMaleMiddle AgedTunisiaXeroderma PigmentosumDNA-Directed DNA PolymeraseRad30 proteinY-Family DNA Polymerases

Identifiers

PMID24877075
PMCPMC4024419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.